Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B88c93ff13415df9058ef3954977e08a3> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B88c93ff13415df9058ef3954977e08a3 NCIT_P378 "NCI" @default.
- B88c93ff13415df9058ef3954977e08a3 type Axiom @default.
- B88c93ff13415df9058ef3954977e08a3 annotatedProperty IAO_0000115 @default.
- B88c93ff13415df9058ef3954977e08a3 annotatedSource NCIT_C152246 @default.
- B88c93ff13415df9058ef3954977e08a3 annotatedTarget "A recombinant humanized immunoglobulin G2 (IgG2) monoclonal antibody directed against sclerostin, with anti-osteoporotic activity. Upon administration, romosozumab targets, binds to and inhibits the activity of sclerostin, a regulatory factor in bone metabolism. This stimulates osteoblastic activity, increases bone formation and, to a lesser extent, decreases bone resorption This may increase trabecular and cortical bone mass and improve bone structure and strength. Altogether, this may decrease the risk of fractures. Sclerostin, a negative regulator of bone formation secreted by osteocytes, inhibits Wnt signaling and suppresses osteoblast development and function." @default.